Publications
5491 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4179), poster 155a; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S2012
SWOG S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide (P/E) with or without Atezolizumab (NSC#783608) in Patients (pts) with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS3644), poster 430A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), poster session
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2201
EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9559), poster 152; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/EA6134
Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy vs targeted therapy in patients (pts) with BRAF mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS9591), poster 183A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- EA6192
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop): ECOG-ACRIN EA6192.
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185), poster 157B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2186
EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT): Trials in Progress
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS6098), poster 89A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster #98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/EA8185
EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration
- Journal / Conference
- Journal of the National Cancer Institute Aug 8;114(8):1059-1064
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID35552713
- PMC
- PMC9360467
Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces
- Journal / Conference
- Journal of Clinical Oncology Jul 20;40(21):2295-2306
- Year
- 2022
- Research Committee(s)
- Lung
- PMID
- PMID35658002
- PMC
- PMC9287284
- Study Number(s)
- S1800A